unusual cranial manifestation of b cell precursor lymphoblastic lymphoma in 10 year old girl

Original title: “An unusual cranial manifestation of B-cell precursor lymphoblastic lymphoma in 10-year-old girl.”

spontaneous regression of b cell acute lymphoblastic leukemia with pax5 alterations at relapse a case report

Original title: “Spontaneous regression of B-cell acute lymphoblastic leukemia with PAX5 alterations at relapse: a case report.”

unusual presentation of philadelphia chromosome positive b cell acute lymphoblastic leukemia with isolated osteolytic lesions at diagnosis a case report

Original title: “An Unusual Presentation of Philadelphia Chromosome Positive B-Cell Acute Lymphoblastic Leukemia With Isolated Osteolytic Lesions at Diagnosis: A Case Report.”

tcf3 hlf positive b all integrated clinical and molecular characterization of 34 cases from a single center cohort

Original title: “TCF3::HLF-positive B-ALL: integrated clinical and molecular characterization of 34 cases from a single-center cohort.”

secondary philadelphia chromosome negative b cell acute lymphoblastic leukemia following prolonged lenalidomide maintenance in multiple myeloma

Original title: “Secondary Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia Following Prolonged Lenalidomide Maintenance in Multiple Myeloma.”

concurrent development of b cell lymphoblastic lymphoma and histiocytic sarcoma in a c57bl 6 laboratory mouse a case report

Original title: “Concurrent Development of B-Cell Lymphoblastic Lymphoma and Histiocytic Sarcoma in a C57BL/6 Laboratory Mouse: A Case Report.”

Real-world inotuzumab ozogamicin boosts remission in relapsed/refractory B-cell ALL, supports transplant, and flags sinusoidal obstruction syndrome risk. Reasonable remission rates were seen when inotuzumab ozogamicin was administered as a salvage therapy to patients with relapsed/refractory B-cell · acute lymphoblastic leukemia (B-ALL), with mean (SD) survival rates of 51.7% (8.1%) overall and 32.4% (8.0%) event-free, according to new research in · Blood Cancer Journal.1 These real-world data are helping to fill a data gap for such evidence currently left by limited studies in this disease and medication, which have been concentrated in clinical trial settings.2-4 Depth of response was clinically meaningful: MRD-negative status occurred in 71.4% of CR/CRi patients, enabling consolidation with ASCT or CAR T in 67.8% overall. Post-therapy hepatic SOS/veno-occlusive disease remained a major toxicity signal, with 9/10 cases after transplant and no clear correlation with cumulative dose or IO–transplant interval. European LeukemiaNet criteria. Of this group, 71.4% (n = 20) reached minimal residual disease–negative status, and 67.8% (n = 19) followed inotuzumab ozogamicin with allogeneic stem cell transplant (ASCT; n = 18) or chimeric antigen receptor (CAR) T-cell therapy (n = 1). Inotuzumab ozogamicin versus FLAG-Ida in the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia – real-world resource use data. Leuk Lymphoma. 2020;61(2):491-493. doi:10.1080/10428194.2019.1672057 · Molina O, Bataller A, Thampi N, et al. Near-haploidy and low-hypodiploidy in B-cell acute lymphoblastic leukemia: when less is too much. Cancers (Basel). 2021;14(1):32. doi:10.3390/cancers14010032 · Hepatic sinusoidal obstruction syndrome (veno-occlusive disease) in adults.

Original title: “Inotuzumab Ozogamicin Outcomes in ALL Validated Outside of Clinical Trials | AJMC”